Gene therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gene therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SnowShredder who wrote (126)	8/13/1999 5:35:00 PM
From: Mike McFarland	Read Replies (1) of 319

AAV--"site specific integration (if they can get it to work efficiently" In the recent Ariad-Genovo paper it was said that there was no reduction in hGH peak levels after each administration of the promoter--for more than ten months. Plus they said they could precisely control the circulating levels of hGH by controlling the rapamycin dose...and if they don't give the drug, hormone levels are undetectable. Is that efficient--or was your question something about directing the therapy to a given site and not having it bleed all through the system? I just assumed you shoot the stuff into a big muscle and most of it stays there. I guess I should go through the papers and keyword search for 'liver'? These were immunocompetent mice that did so well--I assume they're still boppin around with hGH spiked at will. My wife made me sell most of her ARIA when I explained they were working with monkeys, er, non-human primates seems to be the code so the animal rights folks don't perk up...but she let me buy her shares back when it was mice in the latest paper. Funny how nobody seems to be impressed with mice--it's not like they're growing unrealistic tumors on their backs, geeze!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next